VBI Vaccines Inc (VBIV) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
VBI Vaccines Inc. has reported a significant year-over-year revenue increase of 234% for its PreHevbrio Hepatitis B vaccine, with U.S. sales in the first quarter of 2024 already accounting for 65% of the full-year volume of 2023. Positive clinical trial results for VBI-1901 in treating recurrent glioblastoma show potential, with further data expected later in the year. Amid financial market challenges, the company has improved financial stability by strengthening its balance sheet and reducing debt, aiming for sustainable growth and stakeholder value.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.
